Joseph G. Pressey · Targeting wild-type and mutant p53 with small molecule CP-31398 blocks the growth of rhabdomyosarcoma by inducing reactive oxygen species-dependent apoptosis
Follow
Article1 min read·Published Aug 2010Older

Targeting wild-type and mutant p53 with small molecule CP-31398 blocks the growth of rhabdomyosarcoma by inducing reactive oxygen species-dependent apoptosis

pubmed.ncbi.nlm.nih.gov shows its articles on its own site.

Read the article on pubmed.ncbi.nlm.nih.gov ↗

Article · Aug 2010 · 1 min read

In brief

In brief

This preclinical study demonstrates that CP-31398 inhibits rhabdomyosarcoma growth in both wild-type and mutant p53 tumors through mitochondrial-mediated apoptosis and reactive oxygen species generation. The compound reduced tumor xenograft growth and improved survival in animal models, suggesting potential as a therapeutic strategy for this pediatric soft-tissue sarcoma.

Written by the GCMD Library team from the article.

Joseph G. Pressey

Rhabdomyosarcoma (RMS) is a common soft-tissue sarcoma of childhood in need of more effective therapeutic options. The expression of p53 in RMS is heterogeneous such that some tumors are wild-type whereas others are p53 mutant. The small molecule CP-31398 modulates both the wild-type and the mutant p53 proteins. Here, we show that CP-31398 blocks the growth of RMS cells that have either wild-type or mutant p53 status. In wild-type A204 cells, CP-31398 increased the expression of p53 and its downstream transcriptional targets, p21 and mdm2; enhanced the expression of apoptosis-related proteins; and reduced proliferation biomarkers. Flow profiling of CP-31398-treated cells indicated an enhancement in sub-G(0) and G(1) populations. CP-31398 inhibited proliferation in a manner associated with co-induction of SOX9 and p21. Apoptosis induced by CP-31398 occurred with translocation of p53 to mitochondria, leading to altered mitochondrial membrane potential, cytochrome c release, and reactive oxygen species release. In vivo, CP-31398 decreased the growth of tumor xenografts composed of wild-type or mutant p53 tumor cells, increasing tumor-free host survival. Our findings indicate that the ability of CP-31398 to modulate wild-type and mutant p53 results in the inhibition of RMS growth and invasiveness.

Statements in this article

  1. Rhabdomyosarcoma is a common soft-tissue sarcoma of childhood in need of more effective therapeutic options.

    Established
  2. The expression of p53 in rhabdomyosarcoma is heterogeneous such that some tumors are wild-type whereas others are p53 mutant.

    Established
  3. CP-31398 blocks the growth of rhabdomyosarcoma cells that have either wild-type or mutant p53 status.

    Research
  4. In wild-type A204 cells, CP-31398 increased the expression of p53 and its downstream transcriptional targets, p21 and mdm2.

    Research
  5. CP-31398 enhanced the expression of apoptosis-related proteins and reduced proliferation biomarkers in wild-type A204 cells.

    Research
  6. Flow profiling of CP-31398-treated cells indicated an enhancement in sub-G0 and G1 populations.

    Research
  7. CP-31398 inhibited proliferation in a manner associated with co-induction of SOX9 and p21.

    Research
  8. Apoptosis induced by CP-31398 occurred with translocation of p53 to mitochondria, leading to altered mitochondrial membrane potential, cytochrome c release, and reactive oxygen species release.

    Research
  9. CP-31398 decreased the growth of tumor xenografts composed of wild-type or mutant p53 tumor cells in vivo.

    Research
  10. CP-31398 increased tumor-free host survival in xenograft models.

    Research
  11. The ability of CP-31398 to modulate wild-type and mutant p53 results in the inhibition of rhabdomyosarcoma growth and invasiveness.

    Research

Read it at the source ↗

Try
Intelligent Search· scoped to this article · not medical adviceSearch the whole library →
GCMD Library — educational content from recorded physician discussions, not medical advice.